Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22155172 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: Rifaximin-EIR

Indicates status has not been verified in more than two years